We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+13.81%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.53B
AUM Growth
+$567M
Cap. Flow
+$2.93M
Cap. Flow %
0.04%
Top 10 Hldgs %
36.11%
Holding
184
New
8
Increased
71
Reduced
51
Closed
13

Top Buys

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$20.9M
2
INCY icon
Incyte
INCY
+$16.3M
3
ISRG icon
Intuitive Surgical
ISRG
+$14.4M
4
DXCM icon
DexCom
DXCM
+$14.1M
5
CNC icon
Centene
CNC
+$13.5M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$40.9M
2
UNH icon
UnitedHealth
UNH
+$38.4M
3
ELV icon
Elevance Health
ELV
+$26.9M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$24M
5
AXNX
Axonics, Inc. Common Stock
AXNX
+$19M

Sector Composition

Rank Sector Weight
1 Healthcare 99.55%
2 Industrials 0.38%
3 Energy 0.03%
4 Communication Services 0.01%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNDM icon
26
Tandem Diabetes Care
TNDM
$1.15B
$80.5M 1.07%
1,791,450
+225,435
+14% +$10.2M
CLDX icon
27
Celldex Therapeutics
CLDX
$2.87B
$80.2M 1.06%
1,800,000
– –
HCA icon
28
HCA Healthcare
HCA
$82.3B
$79.5M 1.06%
331,306
+45,517
+16% +$10.2M
EW icon
29
Edwards Lifesciences
EW
$49.6B
$79.4M 1.05%
1,064,131
+38,416
+4% +$2.96M
ELV icon
30
Elevance Health
ELV
$82.2B
$76.6M 1.02%
149,421
-53,071
-26% -$26.9M
ARVN icon
31
Arvinas
ARVN
$527M
$73.6M 0.98%
2,150,412
-40,350
-2% -$1.7M
OM icon
32
Outset Medical
OM
$78.4M
$73.4M 0.97%
189,579
+28,415
+18% +$8.01M
OPCH icon
33
Option Care Health
OPCH
$3.42B
$73.1M 0.97%
2,430,422
-198,750
-8% -$6.17M
INSM icon
34
Insmed
INSM
$23.6B
$65.5M 0.87%
3,277,207
+62,503
+2% +$1.21M
EXAS
35
DELISTED
Exact Sciences
EXAS
$65M 0.86%
1,312,015
+182,362
+16% +$7.45M
CRL icon
36
Charles River Laboratories
CRL
$10.5B
$63.2M 0.84%
289,977
+26,984
+10% +$5.89M
RLAY icon
37
Relay Therapeutics
RLAY
$4.41B
$62.8M 0.83%
4,204,820
– –
MOH icon
38
Molina Healthcare
MOH
$11.8B
$61.4M 0.82%
186,014
-54,576
-23% -$18.5M
MGNX icon
39
MacroGenics
MGNX
$291M
$60.3M 0.8%
8,979,913
+1,654,399
+23% +$9.07M
APLS
40
DELISTED
Apellis Pharmaceuticals
APLS
$57.1M 0.76%
1,104,217
+96,773
+10% +$5.13M
CNC icon
41
Centene
CNC
$32.9B
$56.9M 0.75%
693,558
+165,118
+31% +$13.5M
HUM icon
42
Humana
HUM
$48.2B
$56.6M 0.75%
110,539
-23,667
-18% -$12.4M
EVH icon
43
Evolent Health
EVH
$648M
$55.7M 0.74%
1,983,653
+114,598
+6% +$3.29M
SILK
44
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$53.5M 0.71%
1,012,523
-34,833
-3% -$1.7M
PACB icon
45
Pacific Biosciences
PACB
$441M
$53M 0.7%
6,478,925
+1,039,374
+19% +$8.96M
CI icon
46
Cigna
CI
$74.8B
$52.6M 0.7%
158,621
-30,080
-16% -$9.52M
AMED
47
DELISTED
Amedisys
AMED
$51.3M 0.68%
613,512
+14,578
+2% +$1.31M
SWAV
48
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$50.9M 0.68%
247,616
-28,516
-10% -$7.21M
GMED icon
49
Globus Medical
GMED
$10.3B
$50.5M 0.67%
680,180
+33,017
+5% +$2.25M
PEN icon
50
Penumbra
PEN
$12.5B
$50.2M 0.67%
225,817
+36,043
+19% +$7.05M
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2022 Portfolio in Review

As of Q4 2022, Bellevue Group held 184 positions worth $7.53B, up 8.1% from $6.97B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Bellevue Group's Q4 2022 filing shows 8 new, 71 increased, 51 reduced and 13 closed positions. Its largest new stake was Natera: 173,812 shares worth $6.98M. The largest sale was Abiomed Inc, an estimated $40.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Industrials and Energy.

  • Bellevue Group's largest Q4 2022 buy was Natera: 173,812 shares worth $6.98M.
  • Bellevue Group added most to Fate Therapeutics in Q4 2022, an estimated $20.9M increase.
  • Bellevue Group's biggest Q4 2022 reduction was UnitedHealth, cutting an estimated $38.4M.
  • Bellevue Group fully exited Abiomed Inc in Q4 2022, selling an estimated $40.9M.
  • Bellevue Group's ten largest holdings make up 36% of its $7.53B portfolio in Q4 2022.
  • Bellevue Group opened 8 new positions and closed 13 in Q4 2022.
  • Bellevue Group's portfolio value rose 8.1% quarter-over-quarter to $7.53B.

Based on Bellevue Group's 13F filing for Q4 2022, filed 14 Feb 2023.